BVF Inc. IL Sells 279,394 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

BVF Inc. IL cut its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,796,513 shares of the company's stock after selling 279,394 shares during the period. Mirum Pharmaceuticals comprises about 3.9% of BVF Inc. IL's holdings, making the stock its 5th largest holding. BVF Inc. IL owned about 5.82% of Mirum Pharmaceuticals worth $115,636,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of MIRM. Balyasny Asset Management L.P. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth $775,000. Algert Global LLC acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $2,824,000. Schonfeld Strategic Advisors LLC lifted its holdings in Mirum Pharmaceuticals by 2.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 17,200 shares of the company's stock worth $711,000 after buying an additional 487 shares during the last quarter. Northern Trust Corp lifted its holdings in Mirum Pharmaceuticals by 8.7% during the 4th quarter. Northern Trust Corp now owns 399,544 shares of the company's stock worth $16,521,000 after buying an additional 32,059 shares during the last quarter. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $991,000.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright boosted their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of "Buy" and an average target price of $58.20.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM traded up $0.22 during mid-day trading on Wednesday, reaching $41.22. 405,442 shares of the company's stock were exchanged, compared to its average volume of 521,808. The business's fifty day simple moving average is $42.98 and its 200-day simple moving average is $44.17. The stock has a market capitalization of $2.04 billion, a PE ratio of -20.41 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.83 and a 52-week high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. During the same quarter in the prior year, the company posted ($0.54) EPS. Mirum Pharmaceuticals's revenue was up 61.2% on a year-over-year basis. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the transaction, the senior vice president now directly owns 4,841 shares in the company, valued at approximately $214,698.35. This trade represents a 92.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Peter Radovich sold 7,879 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the sale, the chief operating officer now owns 18,672 shares of the company's stock, valued at $825,489.12. This trade represents a 29.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,764 shares of company stock valued at $4,109,161 over the last quarter. 22.87% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.